Trevena, Inc. (NASDAQ:TRVN) has received an average rating of “Buy” from the thirteen ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $11.60.

Several research analysts have issued reports on the company. Zacks Investment Research lowered Trevena from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Cowen and Company restated a “buy” rating and set a $10.00 target price on shares of Trevena in a research report on Friday, August 4th. Finally, Oppenheimer Holdings, Inc. set a $8.00 target price on Trevena and gave the company a “buy” rating in a research report on Thursday, August 3rd.

Several hedge funds and other institutional investors have recently made changes to their positions in TRVN. American International Group Inc. boosted its holdings in shares of Trevena by 7.1% in the first quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 1,816 shares during the period. Nationwide Fund Advisors boosted its holdings in shares of Trevena by 92.1% in the second quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 23,557 shares during the period. Bourgeon Capital Management LLC boosted its holdings in shares of Trevena by 56.8% in the second quarter. Bourgeon Capital Management LLC now owns 53,031 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 19,200 shares during the period. Alliancebernstein L.P. boosted its holdings in shares of Trevena by 51.9% in the second quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 18,900 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of Trevena by 81.0% in the first quarter. SG Americas Securities LLC now owns 35,926 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 16,079 shares during the period. Hedge funds and other institutional investors own 60.09% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/11/trevena-inc-trvn-receives-consensus-rating-of-buy-from-brokerages-2.html.

Shares of Trevena (NASDAQ:TRVN) opened at 2.45 on Wednesday. The company’s 50-day moving average price is $2.49 and its 200 day moving average price is $2.75. The stock’s market capitalization is $146.26 million. Trevena has a one year low of $2.15 and a one year high of $8.00.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.35). Analysts anticipate that Trevena will post ($1.41) EPS for the current year.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.